Fibronectin type III domain containing 5 expression in skeletal muscle in chronic heart failure—relevance of inflammatory cytokines

Journal of Cachexia, Sarcopenia and Muscle

Volumn , Issue , 2015, Pages 62-72

  Matsuo, Yae ^a,b   Gleitsmann, Konstanze ^a   Mangner, Norman ^a   Werner, Sarah ^a   Fischer, Tina ^a   Bowen, T Scott ^a   Kricke, Angela ^a   Matsumoto, Yasuharu ^c   Kurabayashi, Masahiko ^b   Schuler, Gerhard ^a   Linke, Axel ^a   Adams, Volker ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b GUNMA UNIVERSITY   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II; Chronics heart failure; Cytokines; FNDC5; Irisin; Skeletal muscle

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN II DERIVATIVE; FIBRONECTIN; FIBRONECTIN TYPE III DOMAIN CONTAINING 5; GAMMA INTERFERON; INTERLEUKIN 1BETA; IRISIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROTEIN KINASE B; PROTEIN KINASE C; RECOMBINANT ANGIOTENSIN II; RECOMBINANT PROTEIN; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART FAILURE; HEART HEMODYNAMICS; IN VIVO STUDY; ISCHEMIC CARDIOMYOPATHY; MUSCLE ATROPHY; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUADRICEPS FEMORIS MUSCLE; RAT;

EID: 84982104016     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1002/jcsm.12006     Document Type: Article

References (40)

1. Okita K, Kinugawa S, Tsutsui H. Exercise intolerance in chronic heart failure – skeletal muscle dysfunction and potential therapies. Circ J 2013; 77: 293–300.
2. Gielen S, Adams V, Möbius-Winkler S, Linke A, Erbs S, Yu J, Kempf W, Schubert A, Schuler G, Hambrecht R. Antiinflammatory effects of exercise training in the skeletal muscle of patients with Chronic Heart Failure. J Am Coll Cardiol 2003; 42: 861–868.
3. Keith M, Geranmayegan A, Sole MJ, Kurian R, Robinson A, Omran AS, Jeejeebhoy KN. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 1998; 31: 1352–1356.
4. Sukhanov S, Semprun-Prieto L, Yoshida T, Tabony AM, Higashi Y, Galvez S, Delafontaine P. Angiotensin II, oxidative stress and skeletal muscle wasting. Am J Med Sci 2011; 342: 143–147.
5. Li YP, Schwartz RJ, Wadell ID, Holloway BR, Reid MB. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF.kB activation in response to tumor necrosis factor a. FASEB J 1998; 12: 871–880.
6. Szabo T, Postrach E, Mähler A, Kung T, Turhan G, von Haehling S, Anker SD, Boschmann M, Doehner W. Increased catabolic activity in adipose tissue of patients with chronic heart failure. Eur J Heart Fail 2013; 15: 1131–1137.
7. Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol 2012; 8: 457–465.
8. Seldin MM, Wong GW. Regulation of tissue crosstalk by skeletal muscle-derived myonectin and other myokines. Adipocyte 2012; 1: 200–202.
9. Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA, Boström EA, Choi JH, Long JZ, Kajimura MC, Zingaretti MC, Vind BF, Tu H, Cinti S, Holind K, Gygi SP, Spiegelman BM. A PGC1-α dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012; 481: 463–468.
10. Gouni-Berthold I, Berthold HK, Huh JY, Berman R, Spenrath N, Krone W, Mantzoros CS. Effects of lipid-lowering drugs on irisin in human subjects in vivo and in human skeletal muscle cells ex vivo. PLoS One 2013; 8: e72858.
11. Wu J, Boström P, Sparks LM, Ye L, Choi JH, Giang AH, Khandekar M, Virtanen KA, Nuutila P, Schaart G, Huang K, Tu H, Lichtenbelz M, Hoeks J, Enerbäck S, Schrauwen P, Spiegelman BM. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell 2012; 150: 366–376.
12. Lecker SH, Zavin A, Cao P, Arena R, Allsup K, Daniels KM, Joseph J, Schulze PC, Forman DE. Expression of the irisin precursor FNDC5 in skeletal muscle correlates with aerobic exercise performance in patients with heart failure. Circ Heart Fail 2012; 5: 812–818.
13. Huh JY, Panagiotou G, Mougios V, Brinkoetter M, Vamvini MT, Schneider BE, Mantzoros CS. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism 2012; 61: 1725–1738.
14. Vamvini MT, Aronis KN, Panagiotou G, Huh JY, Chamberland JP, Brinkoetter MT, Petrou M, Christophi CA, Kales SN, Christiani DC, Mantzoros CS. Irisin mRNA and circulating levels in relation to other myokines in healthy and morbidly obese humans. Eur J Endocrinol 2013; 169: 829–834.
15. Roberts MD, Bayless DS, Company J, Jenkins NT, Padilla J, Childs TE, Martin JS, Dalbo VJ, Booth FW, Rector RS, Laughlin MH. Elevated skeletal muscle irisin precursor FNDC5 mRNA in obese OLETF rats. Metabolism 2013; 62: 1052–1056.
16. Weisman HF, Bush DE, Mannisi JA, Weisfeldt ML, Healy B. Cellular mechanisms of myocardial infarct expansion. Circulation 1988; 78: 186–201.
17. Adams V, Linke A, Wisloff U, Döring C, Erbs S, Kränkel N, Witt CC, Labeit S, Müller-Werdan U, Schuler G, Hambrecht R. Myocardial expression of Murf-1 and MAFbx after induction of chronic heart failure: effect on myocardial contractility. Cardiovasc Res 2007; 73: 120–129.
18. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995; 270: 27489–27494.
19. Badger AM, Bradbeer JN, Votta B, Lee JC, Adams JL, Griswold DE. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther 1996; 279: 1453–1461.
20. Jove M, Planavilla A, Sanchez RM, Merlos M, Laguna JC, Vazquez-Carrera M. Palmitate induces tumor necrosis factor-alpha expression in C2C12 skeletal muscle cells by a mechanism involving protein kinase C and nuclear factor-kappaB activation. Endocrinology 2006; 147: 552–561.
21. Li YP, Chen Y, John J, Moylan J, Jin B, Mann DL, Reid MB. TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J 2005; 19: 362–370.
22. Wilson C, Contreras-Ferrat A, Venegas N, Osorio-Fuentealba C, Pavez M, Montoya K, Duran J, Maass R, Lavandero S, Estrada M. Testosterone increases GLUT4-dependent glucose uptake in cardiomyocytes. J Cell Physiol 2013; 228: 2399–2407.
23. Nelson EA, Walker SR, Kepich A, Gashin LB, Hideshima T, Ikeda H, Chauhan D, Anderson KC, Frank DA. Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood 2008; 112: 5095–5102.
24. Williamson DL, Bolster DR, Kimball SR, Jefferson LS. Time course changes in signaling pathways and protein synthesis in C2C12 myotubes following AMPK activation by AICAR. Am J Physiol Endocrinol Metab 2006; 291: E80–E89.
25. Georgiadou P, Adamopoulos S. Skeletal muscle abnormalities in chronic heart failure. Curr Heart Fail Rep 2012; 9: 128–132.
26. Adams V, Döring C, Schuler G. Impact of physical exercise on alterations in the skeletal muscle in patients with chronic heart failure. Front Biosci 2008; 13: 302–311.
27. Ferrer-Martinez A, Ruiz-Lozano P, Chien KR. Mouse PeP: a novel peroxisomal protein linked to myoblast differentiation and development. Dev Dyn 2002; 224: 154–167.
28. Strassburg S, Springer J, Anker SD. Muscle wasting in cardiac cachexia. Int J Biochem Cell Biol 2005; 37: 1938–1947.
29. Ventura-Clapier R. Exercise training, energy metabolism, and heart failure. Appl Physiol Nutr Metab 2009; 34: 336–339.
30. Hambrecht R, Fiehn E, Yu J, Niebauer J, Weigl C, Hilbrich L, Adams V, Riede U, Schuler G. Effects of endurance training on mitochondrial ultrastructure and fiber type distribution in skeletal muscle of patients with stable chronic heart failure. J Am Coll Cardiol 1997; 29: 1067–1073.
31. Gielen S, Sandri M, Kozarez I, Kratsch J, Teupser D, Thiery J, Erbs S, Mangner N, Lenk K, Hambrecht R, Schuler G, Adams V. Exercise training attenuates MuRF-1 expression in the skeletal muscle of patients with chronic heart failure independent of age: the randomized Leipzig exercise intervention in chronic heart failure and aging (LEICA) catabolism study. Circulation 2012; 125: 2716–2727.
32. Mangner N, Matsuo Y, Schuler G, Adams V. Cachexia in chronic heart failure: endocrine determinants and treatment perspectives. Endocrine 2013; 43: 253–265.
33. Shan T, Liang X, Bi P, Kuang S. Myostatin knockout drives browning of white adipose tissue through activating the AMPK-PGC1α-FNDC5 pathway in muscle. FASEB J 2013; 27: 1981–1989.
34. Gullestad L, Ueland T, Vinge LE, Finsen A, Yndestad A, Aukrust P. Inflammatory cytokines in heart failure: mediators and markers. Cardiology 2012; 122: 23–35.
35. Hedayat M, Mahmoudi M, Rose N, Rezaei N. Proinflammatory cytokines in heart failure: double-edged swords. Heart Fail Rev 2010; 15: 543–562.
36. Kjaer A, Hesse B. Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives. Clin Physiol 2001; 21: 661–672.
37. Zhang L, Du J, Hu Z, Han G, Delafontaine P, Garcia G, Mitch WE. IL-6 and serum amyloid a synergy mediates angiotensin II-induced muscle wasting. J Am Soc Nephrol 2009; 20: 604–612.
38. Raschke S, Elsen M, Gassenhuber H, Sommerfeld M, Schwahn U, Brockmann B, Jund R, Wisloff U, Tjonna AE, Raastad T, Hallen J, Norheim F, Drevon CA, Romacho T, Eckardt K, Eckel J. Evidence against a beneficial effect of irisin in humans. PLoS One 2013; 8: e73680.
39. Adams V, Nehrhoff B, Späte U, Linke A, Schulze PC, Baur A, Gielen S, Hambrecht R, Schuler G. Induction of iNOS-expression in skeletal muscle by IL-1ß and NFkB activation: an in vitro and in vivo study. Cardiovasc Res 2002; 54: 95–104.
40. Gorman JL, Liu STK, Slopack D, Shariati K, Hasanee A, Olenich S, Olfert IM, Haas TL. Angiotensin II evokes angiogenic signals within skeletal muscle through co-ordinated effects on skeletal myocytes and endothelial cells. PLoS One 2014; 9: e85537.